Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis

NEXT STORY
Outlook Therapeutics Provides Clinical Update on ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
PREV STORY
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

author_avatar
NASDAQ Market News

Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis

author_avatar
NASDAQ Market News

Helsinn supported ‘70 Years of Cancer Care in China’ celebratory event in Shanghai

author_avatar
NASDAQ Market News